CClinicalTrials.gg
CompletedNCT03447548Updated Feb 28, 2024

Neurofeedback Training for High Risk Psychosis

An interventional study of Neurofeedback processing speed training and Active control in Prodromal Schizophrenia, sponsored by Hartford Hospital. Completed at 2 sites in United States. Open to participants aged 12 Years to 25 Years. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Hartford Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
12 Years to 25 Years
Sex
All
01

Study summary

Young people who are at great risk for developing psychosis have cognitive deficits which are strongly related to functioning in the community. This study looks to target a specific cognitive skill called processing speed to see if improving the ability to process information in a timely manner will improve social function in adolescents and young adults at risk for developing schizophrenia. Half will receive neurofeedback cognitive training targeting processing speed while the other half will receive an active control.

Read the detailed description

Processing speed deficits are characteristic of schizophrenia and related to its functional impairment, including in its nascent stages, during a putatively prodromal or clinical high risk period. These cognitive deficits have proven relatively refractory to pharmacologic strategies, though the deficits can be improved with cognitive remediation programs in schizophrenia. The cognitive gains can then generalize to functional improvement, particularly early in the course of illness (i.e. first episode psychosis). Although processing speed deficits are also prevalent in young people identified as at clinical high risk for psychosis (i.e. "psychosis risk syndrome"), and related to their concurrent impaired function and predictive of later psychosis (onset of which occurs in 20-25% of clinical high risk cohorts), little research has focused on how to remediate these deficits in clinical high risk patients. Remediating core cognitive deficits in clinical high risk patients could plausibly address present functional impairment in these young people and moderate illness progression. The investigators propose to conduct a double-blind randomized trial in 105 clinical high risk patients to examine a focal processing speed training program versus an active control in terms of improvement in processing speed and social function, and reduction in prodromal symptom severity.

02

Conditions studied

  • Prodromal Schizophrenia

Browse trials for

Keywords

  • Cognitive training
  • Social function
  • Processing speed
03

Who can participate

Ages eligible
12 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Case identification and ascertainment depends on the fulfillment of the Criteria of Prodromal States as evaluated using the Structured Interview for Prodromal Syndromes: (1) attenuated positive symptom state which includes the emergence or worsening over the past year of non-psychotic disturbances in thought content, thought process or perceptual abnormality, (2) brief intermittent positive symptoms, and (3) genetic risk and deterioration.
  • Processing speed at least 0.5 Standard Deviation below the norm, as indexed by baseline performance on Digit Symbol Coding of 8 or below
  • Age range 12-25 (this age range also comprises the main period of risk for psychosis)
  • Written informed consent by patients >18 years old, and written assent by subjects \<18 years old, with written informed consent by both parents (unless one is deceased or unavailable). Participants who turn 18 while in the study will be re-consented as adults through written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Current or past diagnosis of psychotic disorder noted at baseline assessment (schizophrenia, schizophreniform, bipolar, schizoaffective, major depression with psychotic features, substance-induced psychosis, psychosis due to a medical condition.
  • Neurological, neuroendocrine or major medical disorders: as putative prodromal symptoms could be secondary to these and unrelated to risk for primary psychotic disorders (clinical interview), including seizure disorder and history of significant traumatic brain injury
  • Intelligence Quotient \< 70: as putative prodromal symptoms could be secondary to these and unrelated to risk for primary psychotic disorders
  • Positive symptoms that occur only in the context of substance abuse or withdrawal (i.e. within one month), so as not to include those at risk for substance-induced psychotic disorder
  • Lack of fluency in English: subjects must speak English to complete behavioral assessments for which psychometric properties have been established in English, complete cognitive training, and in order to comprehend and comply with protocol requirements.
  • Substance abuse or dependence (including alcohol and marijuana) in previous six months: for purposes of standardization and interpretation of cognitive data.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Processing speed training

    Neurofeedback processing speed training

    Behavioral: Neurofeedback processing speed training

  • Active comparator
    Active control

    Computer games

    Behavioral: Active control

Interventions

  • BehavioralNeurofeedback processing speed training

    Processing speed training on tablets that incorporates changes in pupil size to titrate the learning algorithm

  • BehavioralActive control

    Commercially available games on tablet

05

What researchers measure

Primary outcomes

  1. Change on the Wechsler Intelligence Scale Processing Speed Index

    Change on a paper and pencil test of processing speed

    Time frame: Baseline, 1 month, 2 month, 6 month

06

Study locations

2 sites
  • Connecting Adolescents with Psychosis (CAP), Child & Adolescents Day Program
    Hartford, Connecticut 06106, United States
  • Olin Neuropsychiatry Research Center
    Hartford, Connecticut 06106, United States
07

Registry details

Key details

Study ID
NCT03447548
Lead sponsor
Hartford Hospital
Collaborators
National Institute of Mental Health (NIMH)
Responsible party
Sponsor
First posted
Feb 27, 2018
Start date
Mar 1, 2018
Primary completion
Dec 1, 2021
Completion
Dec 1, 2021
Last update
Feb 28, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion